This is a case-control cross-sectional study conducted from September 2013 to September 2017 at Farabi Eye Hospital in Tehran, Iran. Three groups of subjects were investigated in this study as follows: (1) pseudoexfoliation eyes with glaucoma (“PXG” group), (2) age-matched PXS eyes without glaucoma (“PXS” group), and (3) age-matched healthy volunteers (“control” group). Controls were selected among individuals who were referred to the hospital for routine and/or refractive check-ups. A complete ophthalmic examination was performed for all subjects, including best-corrected visual acuity measurement (using the Early Treatment Diabetic Retinopathy Study chart), slit-lamp biomicroscopy, Goldmann applanation tonometry, gonioscopy, dilated stereoscopic fundus examination using a 90- or 78-diopter (D) lens, measurement of the central corneal thickness by pachymetry (Tomey Corporation, Nagoya, Japan), visual field test (Humphrey Field Analyzer II 750; 24-2 Swedish interactive threshold algorithm; Carl Zeiss Meditec, Dublin, CA, USA), axial length measurement (IOLMaster; Carl Zeiss Meditec), and SD-OCT imaging of the ONH and macula (Spectralis OCT; Heidelberg Engineering, Inc., Dossenheim, Germany).
For all study participants, inclusion criteria were as follows: (1) age above 18 years; (2) best-corrected visual acuity of 0.5 logMAR or better with a spherical equivalent within 5 D and a cylinder correction within 3 D; and (3) reliable Humphrey Field Analyzer results with a false-positive error rate less than 15%, a false-negative error rate less than 20%, and a fixation loss rate less than 20%. The exclusion criteria were as follows: (1) presence of other intraocular or neurologic disorder that could cause visual field impairment; (2) history of any ocular surgery; (3) a diagnosis of glaucoma in the fellow eye; (4) hazy media interfering with OCT imaging; or (5) history of diabetes mellitus.
Patients were enrolled in the PXG group if they had (1) pseudoexfoliation material on the anterior lens capsule and/or pupillary margin after mydriasis on slit-lamp biomicroscopy; (2) glaucomatous optic neuropathy (thinning or notching of the neural rim); (3) glaucomatous visual field defect defined as a Glaucoma Hemifield Test outside of normal limits and four abnormal points with
P < 5% on the pattern deviation plot, both confirmed at least once on 24-2 visual fields
34; and (4) history of IOP greater than 21 mm Hg without treatment. The PXS group were defined as (1) visible pseudoexfoliation material on the anterior lens capsule and/or pupillary margin after mydriasis on slit-lamp biomicroscopy; (2) IOP less than 22 mm Hg without treatment; (3) negative history of elevated IOP; (4) absence of glaucomatous disc appearance (i.e., intact neuroretinal rim without cupping, notches, or localized pallor); and (5) a normal standard automated perimetry defined by mean deviation (MD) and pattern standard deviation (PSD) within 95% CI limits and a Glaucoma Hemifield Test within normal limits. The control group was defined as (1) IOP less than 22 mm Hg without treatment; (2) negative history of elevated IOP; (3) absence of glaucomatous disc appearance; (4) normal standard automated perimetry; and (5) absence of pseudoexfoliation material on the anterior lens capsule or pupillary margin after mydriasis on slit-lamp biomicroscopy in both eyes.
This study was approved by the local Ethical Committee of Tehran University of Medical Sciences and was conducted in accordance with the Declaration of Helsinki. All patients provided written informed consent prior to enrollment in the study.